1 / 44

New Strategies for Treatment: Pancreatic Adenocarcinoma

New Strategies for Treatment: Pancreatic Adenocarcinoma. Program Goal. Difficult Disease to Treat. Aggressive, Invasive, Metastatic. Molecular Progression Model of Pancreatic Cancer (PanINs). End-Stage Disease: “Proving Ground”. Metastatic vs Locally Advanced Disease.

macon-dyer
Download Presentation

New Strategies for Treatment: Pancreatic Adenocarcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Strategies for Treatment: Pancreatic Adenocarcinoma

  2. Program Goal

  3. Difficult Disease to Treat

  4. Aggressive, Invasive, Metastatic

  5. Molecular Progression Model of Pancreatic Cancer (PanINs)

  6. End-Stage Disease: “Proving Ground”

  7. Metastatic vs Locally Advanced Disease

  8. Gemcitabine vs Fixed-Dose-Rate Gemcitabine vs Gemcitabine Plus Oxaliplatin

  9. Gemcitabine vs Gemcitabine Plus Cetuximab

  10. Gemcitabine vs Gemcitabine Plus Bevacizumab

  11. Gemcitabine vs Gemcitabine Plus Cisplatin

  12. Gemcitabine vs Gemcitabine Plus Capecitabine

  13. Gemcitabine vs Gemcitabine Plus Erlotinib

  14. PRODIGE 4/ACCORD 11 Trial Design

  15. Experimental Arm: FOLFIRINOX

  16. FOLFIRINOX vs Gemcitabine: Overall Survival

  17. Safety: Main Nonhematologic Adverse Effects (% per Patient)

  18. Patient Characteristics

  19. What Other Regimens Are There?

  20. Gemcitabine and Cisplatin

  21. Gemcitabine vs Gemcitabine Plus Capecitabine

  22. Gemcitabine Plus nab-Paclitaxel

  23. GTX Regimen

  24. Modified GTX Regimen

  25. Second-Line Therapies?

  26. Pathways: Tumor Microenvironment

  27. IPI-926 Plus GemcitabineDecrease in CA 19-9 in Majority of Patients

  28. Durable Responses and Stable Disease

  29. Examples of Potential Targets

  30. K-Ras Pathway Inhibition

  31. Phase 2: ISIS-2503 Plus Gemcitabine

  32. IGF-R1 Inhibitor Studies

  33. HER2 Inhibition

  34. PARP Inhibitor ABT-888: Phase 1/2

  35. Phase 1: Selective Akt Inhibitor, MK-2206

  36. AGS-1C4D4 Plus Gemcitabine

  37. Inhibiting the Microenvironment

  38. Conclusions

  39. Thank you for participatingin this activity.

More Related